Based on the results of the ADAURA trial [18], adjuvant use of osimertinib has become part of the recommended standard of care for patients with resected stage IB-IIIA (American Joint Committee on Cancer [AJCC] 7th edition) NSCLC that harbors sensitizing EGFR mutations (EGFRm) [8,19,20]. Here, EGFR is linked to non-small cell lung carcinoma.